Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rush University Medical Center
Headquarters: Chicago, IL, United States of America
Website: http://www.rush.edu
Year Founded: N/A
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | May 6, 2022
Discovery & Translation
Sanofi and ModeX’s Epstein-Barr vaccine; plus San Raffaele, Walden and more
BioCentury’s roundup of translational news
BioCentury | Feb 12, 2022
Discovery & Translation
More efficient RNA base editing, TCR constructs targeting WT1 epitopes and more
BioCentury’s roundup of translational news
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Oct 29, 2021
Emerging Company Profile
Walden: targeting podocytes as linchpin for kidney function
Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases
BioCentury | Oct 1, 2021
Distillery Therapeutics
Targeting the TLR2/MYD88/NF-κB pathway for α-synucleinopathies
BioCentury | Sep 23, 2021
Management Tracks
Alnylam vet Smith joins MPM
Plus: Yi to leave Cerevel, Dicerna, Verastem, MiroBio,
BioCentury | Oct 2, 2020
Distillery Therapeutics
IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis
DISEASE CATEGORY: Autoimmune disease
INDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA) Monomers of IL-12B, which can dimerize with itself, IL-12A or IL23P19, could treat autoimmune
INDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA) Monomers of IL-12B, which can dimerize with itself, IL-12A or IL23P19, could treat autoimmune
BioCentury | Oct 23, 2019
Company News
Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio
Items per page:
1 - 10 of 37